The New 3rd Board: a boon to the Chinese OTC market

The New 3rd Board: a boon to the Chinese OTC mark...

Our View - Issue VIII, September 2015

1000

Related content

Our View

In this issue of “Our view” we delve into some of the issues regarding how Shanghai’s emerging ‘New 3rd Board’ has been affecting M&A. Points of note include:

  • a fundamental shift in China’s OTC capital markets and how small and mid-sized firms are availing of the various opportunities
  • how Shanghai’s New 3rd Board is emerging as an alternative listing option, creating new challenges for inbound M&A
  • the relatively high index levels being used as a benchmark by some China firms in deal negotiations in respect to valuations.

Connect with us

KPMG's new digital platform

KPMG International has created a state of the art digital platform that enhances your experience, optimized to discover new and related content.